Transcatheter Edge-to-Edge Repair (TEER)
Treatment for Non Rheumatic Degenerative Mitral Valve Disease
Effectiveness
75%
Safety Score
60%
Clinical Trials
100
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Time to Effect
1-3 months for symptom improvement
Treatment Duration
One-time procedure
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$2,000
Side Effect Mgmt:$750
Total Annual:$2,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$3,437.5
Cost per Remission
$5,000
Comparison vs Medical Management
Cost Difference
+$90,000/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
Transcatheter Edge-to-Edge Repair (TEER) Outcomes
for Non Rheumatic Degenerative Mitral Valve Disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+80%
Remission Rate
+55%
Common Side Effects
Vascular complications (access site)
+7%
New-onset Atrial Fibrillation
+7%
MR recurrence/residual MR
+15%
Single-leaflet device thrombosis
+0.5%
In-hospital Mortality
+3.5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov